These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11072484)

  • 1. Comparison of risperidone and other neuroleptics in the management of chronic schizophrenia using cognitive therapy.
    Azhar MZ
    Med J Malaysia; 2000 Mar; 55(1):7-13. PubMed ID: 11072484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
    Pajonk FG
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):15-23. PubMed ID: 14687852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive-behavioral therapy for medication-resistant schizophrenia: a review.
    Rathod S; Kingdon D; Weiden P; Turkington D
    J Psychiatr Pract; 2008 Jan; 14(1):22-33. PubMed ID: 18212600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of risperidone on cognitive functions in schizophrenia.
    Barkić J; Filaković P; Radanović-Grgurić L; Koić O; Laufer D; Pozgain I; Koić E; Hotujac L
    Coll Antropol; 2003; 27 Suppl 1():111-8. PubMed ID: 12955900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reemergence of positive symptoms after initial response to risperidone.
    Cung DD; Stimmel GL
    Pharmacotherapy; 1997; 17(2):383-6. PubMed ID: 9085334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
    Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
    Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
    Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia].
    Borkowska A; Rybakowski J
    Psychiatr Pol; 2002; 36(6 Suppl):225-33. PubMed ID: 12647443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
    Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients].
    Reinares M; Martínez-Arán A; Colom F; Benabarre A; Salamero M; Vieta E
    Actas Esp Psiquiatr; 2000; 28(4):231-8. PubMed ID: 11116794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission in schizophrenia: analysis in a naturalistic setting.
    Eberhard J; Levander S; Lindström E
    Compr Psychiatry; 2009; 50(3):200-8. PubMed ID: 19374962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.